NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone515-296-5555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.47 million
Profitability
Miscellaneous
Employees55
Next Earnings Date7/30/2019 (Estimated)
OptionableOptionable
NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions
What is NewLink Genetics' stock symbol?
NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."
How were NewLink Genetics' earnings last quarter?
NewLink Genetics Corp (NASDAQ:NLNK) released its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.04. The biotechnology company had revenue of $0.11 million for the quarter. NewLink Genetics had a negative return on equity of 38.63% and a negative net margin of 1,691.08%. View NewLink Genetics' Earnings History.
When is NewLink Genetics' next earnings date?
What price target have analysts set for NLNK?
3 brokerages have issued 1-year price objectives for NewLink Genetics' shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate NewLink Genetics' share price to reach $4.3333 in the next year. This suggests a possible upside of 176.0% from the stock's current price. View Analyst Price Targets for NewLink Genetics.
What is the consensus analysts' recommendation for NewLink Genetics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NewLink Genetics.
Has NewLink Genetics been receiving favorable news coverage?
News headlines about NLNK stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. NewLink Genetics earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting NewLink Genetics?
NewLink Genetics saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 2,282,855 shares, an increase of 36.9% from the March 29th total of 1,668,089 shares. Based on an average daily trading volume, of 723,397 shares, the days-to-cover ratio is currently 3.2 days. Currently, 7.9% of the shares of the company are short sold. View NewLink Genetics' Current Options Chain.
Who are some of NewLink Genetics' key competitors?
Some companies that are related to NewLink Genetics include Aclaris Therapeutics (ACRS), Minerva Neurosciences (NERV), Kamada (KMDA), Cerecor (CERC), AcelRx Pharmaceuticals (ACRX), Edge Therapeutics (EDGE), Verrica Pharmaceuticals (VRCA), Urovant Sciences (UROV), Mersana Therapeutics (MRSN), Calithera Biosciences (CALA), Syros Pharmaceuticals (SYRS), Millendo Therapeutics (MLND), Tocagen (TOCA), Spero Therapeutics (SPRO) and Affimed (AFMD).
What other stocks do shareholders of NewLink Genetics own?
Who are NewLink Genetics' key executives?
NewLink Genetics' management team includes the folowing people:
- Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
- Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
- Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
- Mr. Brian Wiley, Chief Commercial Officer (Age 51)
- Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)
Who are NewLink Genetics' major shareholders?
NewLink Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (7.30%), BlackRock Inc. (4.87%), Oxford Asset Management LLP (1.27%), Acadian Asset Management LLC (1.08%), Dimensional Fund Advisors LP (0.85%) and JPMorgan Chase & Co. (0.72%). Company insiders that own NewLink Genetics stock include Carl W Langren, Ernest Talarico III and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.
Which major investors are selling NewLink Genetics stock?
NLNK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Oxford Asset Management LLP, Morgan Stanley, Dimensional Fund Advisors LP, BlackRock Inc. and California State Teachers Retirement System. View Insider Buying and Selling for NewLink Genetics.
Which major investors are buying NewLink Genetics stock?
NLNK stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Virtu Financial LLC, Pennsylvania Trust Co, Parametric Portfolio Associates LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for NewLink Genetics.
How do I buy shares of NewLink Genetics?
Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NewLink Genetics' stock price today?
One share of NLNK stock can currently be purchased for approximately $1.57.
How big of a company is NewLink Genetics?
NewLink Genetics has a market capitalization of $58.53 million and generates $12.47 million in revenue each year. The biotechnology company earns $-53,600,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.
What is NewLink Genetics' official website?
How can I contact NewLink Genetics?
NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]
MarketBeat Community Rating for NewLink Genetics (NASDAQ NLNK)
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
